Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational allogeneic cell therapy consists of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) and is being developed by Fu-Sheng Wang and colleagues at the Fifth Medical Center of Chinese PLA General Hospital. The therapy is specifically targeted toward HIV-infected immune non-responders (INRs)—patients who fail to achieve adequate CD4+ T cell recovery despite maintaining viral suppression through long-term antiretroviral therapy (ART). UC-MSCs possess potent immunomodulatory and anti-inflammatory properties, which are utilized to counteract the chronic immune activation and systemic inflammation that drive T cell depletion in these patients. By modulating the immune environment, the therapy aims to facilitate the restoration of CD4+ T cell counts and improve overall immune function. It has been evaluated in a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial (NCT01213186).
- Other names
- human umbilical cord-derived mesenchymal stem cellsallogeneic umbilical cord mesenchymal stem cellsmesenchymal stem cells-Fu-Sheng Wang-HIV infection
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).